Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report

Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus

“…Mesalaminerelated nephrotoxicity can be a serious complication and delays in diagnosis and treatment discontinuation can lead to end-stage renal disease [ 6 , 9 , 10 ]. Moreover, nephrotoxicity has also been reported with anti-tumor necrosis factors agents (anti-TNF) and with vedolizumab [11][12][13][14] . Finally, kidney-related extra-intestinal manifestations (EIMs) (e.g., nephrolithiasis, tubulointerstitial nephritis, glomerulonephritis or amyloidosis) can also occur along IBD course independently to the associated treatments [15][16][17] .…”

Republished: Acute interstitial nephritis secondary to vedolizumab

“…The episodes of myalgia and fever lead to her admission to hospital in June 2020 when renal function dysfunction was initially detected. A previous report of AIN secondary to vedolizumab similarly highlights myalgia and fever as initial symptoms reported by their patient 4. The delayed onset of AIN following initiation of vedolizumab may be explained by the frequent courses of steroids having a masking effect.…”

“…On review of published case reports, we have found one case of interstitial nephritis secondary to vedolizumab treatment in Crohn’s disease 4. In this case, the patient developed vomiting, asthenia, myalgia and fever 6 hours following vedolizumab administration.…”

Renal involvement in paediatric inflammatory bowel disease

“…Vedolizumab was initially thought to be renal friendly, but at least one published case reports an acute interstitial nephritis secondary to vedolizumab. The renal injury recovered completely with systemic steroids and the authors were able to reintroduce Vedolizumab with pre-and postadministration steroid cover with no further effects on renal function [63].…”